Entire sample (n = 101) | Patients with followup (n = 62) | |
---|---|---|
Age (years) | 63.77 ± 7.17 | 64.24 ± 7.64 |
Number of inhalers | 2.59 ± 0.59 | 2.52 ± 0.57 |
FEV1 (L) | 1.29 ± 0.56 (n = 94) | 1.28 ± 0.53 (n = 18) |
FEV1% expected | 50.85 ± 19.24 (n = 96) | 51.83 ± 18.77 (n = 18) |
CAT score | 23.09 ± 7.84 (n = 95) | 23.71 ± 7.45 (n = 59) |
Number of errors | 3.17 ± 1.57 | 3.11 ± 1.54 |
Years of inhaler use | 8.67 ± 10.41 | 8.95 ± 10.8 |
Follow-up interval (months) | NA | 4.69 ± 2.6 |
FEV1/ FVC | 49.12 ± 12.52 (n = 81) | |
Male sex | 40 (40%) | 23 (37%) |
Active smoking | 34 (34%) | 19 (31%) |
LABA | 81 (80%) | 51 (82%) |
LAMA | 84 (83%) | 51 (82%) |
ICS | 68 (67%) | 40 (65%) |
SABA | 92 (91%) | 57 (92%) |
SAMA | 6 (6%) | 4 (6%) |
Montelukast | 2 (2%) | 2 (3%) |
Theophylline | 1 (1%) | 0 (0%) |
Race | ||
Asian | 3 (3%) | 0 (0%) |
Black | 55 (54%) | 34 (55%) |
White | 38 (38%) | 26 (42%) |
Other | 5 (5%) | 2 (3%) |
RCS Score | Entire sample (n = 62) | – |
Normal | 28 (45%) | – |
Mild Impairment | 19 (31%) | – |
Dementia | 13 (21%) | – |
Unknown | 2 (3%) | – |